Last10K.com

Celyad Oncology Sa (CYAD) SEC Filing 20-F Annual report for the fiscal year ending Thursday, December 31, 2020

Celyad S.A.

CIK: 1637890 Ticker: CYAD

View differences made from one year to another to evaluate Celyad S.A.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 20-F Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Celyad S.A..

Continue

Assess how Celyad S.A.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Celyad S.A.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 20-F Annual Report

Cover Page
Consolidated Statements Of Cash Flows
Consolidated Statements Of Changes In Shareholders' Equity
Consolidated Statements Of Comprehensive Income / (Loss)
Consolidated Statements Of Financial Position
Consolidated Statements Of Income (Loss)
Accounting Principles
Accounting Principles (Policies)
Accounting Principles (Tables)
Accounting Principles - Additional Information (Detail)
Accounting Principles - Summary Of Transition Impact (Detail)
Advances Repayable
Advances Repayable (Tables)
Advances Repayable - Additional Information (Detail)
Advances Repayable - Certain Terms And Conditions For Recoverable Cash Advances (Detail)
Advances Repayable - Summary Of Current And Non-Current Portion Financial Liabilities (Detail)
Advances Repayable - Summary Of Information On Other Outstanding Advances (Detail)
Cash And Cash Equivalents
Cash And Cash Equivalents (Tables)
Cash And Cash Equivalents - Additional Information (Detail)
Cash And Cash Equivalents - Summary Of Cash And Cash Equivalents (Detail)
Change In Fair Value Of Contingent Consideration, Other Income And Other Expenses
Change In Fair Value Of Contingent Consideration, Other Income And Other Expenses (Tables)
Change In Fair Value Of Contingent Consideration, Other Income And Other Expenses - Additional Information (Detail)
Change In Fair Value Of Contingent Consideration, Other Income And Other Expenses - Schedule Of Change In Fair Value Of Contingent Consideration (Detail)
Change In Fair Value Of Contingent Consideration, Other Income And Other Expenses - Summary Of Other Expenses (Detail)
Change In Fair Value Of Contingent Consideration, Other Income And Other Expenses - Summary Of Other Income (Detail)
Changes In Liabilities Arising From Financial Activities
Changes In Liabilities Arising From Financial Activities (Tables)
Changes In Liabilities Arising From Financial Activities - Additional Information (Detail)
Changes In Liabilities Arising From Financial Activities - Fair Value Measurements Using Significant Unobservable Inputs (Detail)
Commitments
Commitments - Additional Information (Detail)
Critical Accounting Estimates And Judgments
Critical Accounting Estimates And Judgments - Additional Information (Detail)
Deferred Taxes
Deferred Taxes (Tables)
Deferred Taxes - Schedule Of Deferred Tax Assets And Liabilities (Detail)
Deferred Taxes - Schedule Of Unrecognised Deferred Tax Asset Balance Roll Forward (Detail)
Due Dates Of The Financial Liabilities
Due Dates Of The Financial Liabilities (Tables)
Due Dates Of The Financial Liabilities - Aggregate Information Material Contractual Obligations And Payments Due (Detail)
Employee Benefit Expenses
Employee Benefit Expenses (Tables)
Employee Benefit Expenses - Additional Information (Detail)
Employee Benefit Expenses - Summary Of Employee Expenses (Detail)
Events After The Close Of The Fiscal Year
Events After The Close Of The Fiscal Year - Additional Information (Detail)
Financial Income And Expenses
Financial Income And Expenses (Tables)
Financial Income And Expenses - Additional Information (Detail)
Financial Income And Expenses - Summary Of Financial Revenues And Expenses (Detail)
Financial Instruments
Financial Instruments (Tables)
Financial Instruments - Schedule Of Sensitivity Analysis On Fair Value Of Contingent Consideration (Detail)
Financial Instruments - Summary Of Carrying And Fair Values Of Financial Instruments That Are Not Reported At Fair Value (Detail)
Financial Instruments - Summary Of Carrying And Fair Values Of Financial Instruments That Are Reported At Fair Value (Detail)
Financial Instruments - Summary Of Contingent Consideration And Other Financial Liabilities (Detail)
General Information And Statement Of Compliance
General Information And Statement Of Compliance - Additional Information (Detail)
Income Tax
Income Tax (Tables)
Income Tax - Additional Information (Detail)
Income Tax - Schedule Of Reconciliation Between Effective And Theoretical Income Tax (Detail)
Income Tax Expense - Summary Of Group Reports Income Taxes In The Income Statement (Detail)
Income Tax Expense - Summary Of Group Reports Income Taxes In The Income Statement (Parenthetical) (Detail)
Intangible Assets
Intangible Assets (Tables)
Intangible Assets - Additional Information (Detail)
Intangible Assets - Summary Of Intangible Assets (Detail)
Intangible Assets - Summary Of Probabilities Of Success For Products (Detail)
Intangible Assets - Summary Of Sensitivity Analyses Of Recoverable Amount Of Cgu (Detail)
Inventories And Work In Progress
Investment In Subsidiaries
Investment In Subsidiaries (Tables)
Investment In Subsidiaries - Summary Of Consolidated Subsidiaries (Detail)
Leases
Leases (Tables)
Leases - Additional Information (Detail)
Leases - Summary Of Cash Outflow For Leases (Detail)
Leases - Summary Of Lease Expense (Detail)
Leases - Summary Of Property Plant And Equipment Owned And Leased Assets (Detail)
Leases - Summary Of Rights To Use Assets (Detail)
Loss Per Share
Loss Per Share (Tables)
Loss Per Share - Calculation Of Earnings (Loss) Per Share (Detail)
Operating Expenses
Operating Expenses (Tables)
Operating Expenses - Additional Information (Detail)
Operating Expenses - Summary Of General And Administrative Expenses (Detail)
Operating Expenses - Summary Of Research And Development Expenses (Detail)
Operating Segment Information
Operating Segment Information (Tables)
Operating Segment Information - Additional Information (Detail)
Operating Segment Information - Schedule Of Segment Profit By Operating Segment (Detail)
Other Non-Current Assets
Other Non-Current Assets (Tables)
Other Non-Current Assets - Additional Information (Detail)
Other Non-Current Assets - Summary Of Detailed Information About Non-Current Trade Receivables (Detail)
Other Non-Current Assets - Summary Of Non-Current Financial Assets (Detail)
Other Non-Current Liabilities
Other Non-Current Liabilities (Tables)
Other Non-Current Liabilities - Additional Information (Detail)
Other Non-Current Liabilities - Summary Of Other Non-Current Liabilities (Detail)
Other Reserves
Other Reserves (Tables)
Other Reserves - Addtional Information (Detail)
Other Reserves - Summary Of Information On Other Reserves (Detail)
Post Employment Benefits - Additional Information (Detail)
Post Employment Benefits - Summary Of Change In Defined Benefit Liability (Detail)
Post Employment Benefits - Summary Of Defined Benefit Amounts Recognized In The Statement Of Financial Position (Detail)
Post Employment Benefits - Summary Of Income Statement Charge Included In Operating Profit For Post- Employment Benefits (Detail)
Post Employment Benefits - Summary Of Pension Obligations (Detail)
Post Employment Benefits - Summary Of Re-Measurements Included In Other Comprehensive Loss (Detail)
Post-Employment Benefits
Post-Employment Benefits (Tables)
Property, Plant And Equipment
Property, Plant And Equipment (Tables)
Property, Plant And Equipment - Additional Information (Detail)
Property, Plant And Equipment - Summary Of Changes In Carrying Value Of Property, Plant And Equipment (Detail)
Relationships With Related Parties
Relationships With Related Parties (Tables)
Relationships With Related Parties - Summary Of Remuneration Of Key Management Informations (Detail)
Relationships With Related Parties - Summary Of Transactions With Non-Executive Directors (Detail)
Revenues
Revenues - Summary Of Revenues (Detail)
Revenues (Tables)
Revenues - Additional Information (Detail)
Risk Management
Risk Management - Additional Information (Detail)
Share Capital
Share Capital (Tables)
Share Capital Issued - Additional Information (Detail)
Share Capital Issued - Summary Of Share Capital Issued (Detail)
Share Capital Issued - Summary Of Share Issuances Occurred Since The Incorporation Of The Company (Detail)
Share-Based Payments
Share-Based Payments (Tables)
Share-Based Payments - Additional Information (Detail)
Share-Based Payments - Changes In Number Of Warrants Outstanding (Detail)
Share-Based Payments - Summary Of Fair Value Of Warrants Determined At Grant Date (Detail)
Share-Based Payments - Summary Of Warrants Outstanding (Detail)
Short Term Investments
The Company
The Company - Additional Information (Detail)
Trade Payables And Other Current Liabilities
Trade Payables And Other Current Liabilities (Tables)
Trade Payables And Other Current Liabilities - Additional Information (Detail)
Trade Payables And Other Current Liabilities - Trade Payables And Other Current Liabilities (Detail)
Trade, Other Receivables And Other Assets
Trade, Other Receivables And Other Assets (Tables)
Trade, Other Receivables And Other Assets - Additional Information (Detail)
Trade, Other Receivables And Other Assets - Summary Of Trade Receivables And Other Assets (Detail)

Material Contracts, Statements, Certifications & more

Celyad S.A. provided additional information to their SEC Filing as exhibits

Ticker: CYAD
CIK: 1637890
Form Type: 20-F Annual Report
Accession Number: 0001193125-21-092779
Submitted to the SEC: Wed Mar 24 2021 5:16:39 PM EST
Accepted by the SEC: Wed Mar 24 2021
Period: Thursday, December 31, 2020
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/cyad/0001193125-21-092779.htm